Saudi SFDA unregistered drug pathway

What this pathway actually is

In Saudi Arabia, access to a specialty medicine that is not locally registered — or is registered but unavailable in sufficient quantity — runs through the SFDA. The mechanism is not a loophole; it is a formally recognized pathway that allows a named patient, prescribed by a licensed local physician, to import a specific quantity of a specific medicine for personal clinical use. The legal basis is different in each jurisdiction, but the operational shape is similar: a prescription, a clinical justification, an import permit or ethics clearance, and a compliant supply chain from the source country to the treating hospital or pharmacy.

Who can initiate a request

In almost every Saudi Arabia-type pathway, the initiator must be a licensed physician with standing to prescribe in the destination country. A patient or family cannot self-initiate the filing; they can request that their physician file on their behalf. Reserve Meds does not replace that physician. What we do is equip the physician with the sourcing documentation, DSCSA-provenanced US supply, and logistics coordination that lets the filing move through the authority’s queue without avoidable rework.

Documents commonly required

Documentation requirements vary, but a common working set includes: a prescription from the treating physician specifying drug, strength, dose, and duration; a clinical justification letter explaining why alternatives are not appropriate; a patient consent form (sometimes witnessed); a copy of the patient’s identity document; hospital or clinic letterhead with the treating physician’s credentials; a pro-forma invoice from the supplying entity; and DSCSA transaction documentation from the source-country wholesaler. Country-specific forms may add an ethics-committee opinion, a pharmacovigilance commitment, or a local-distributor attestation.

Timeline expectations

From a clean filing, typical timelines in Saudi Arabia run from a few business days (for routine unregistered imports with good documentation) to several weeks (for first-of-kind therapies, gene therapies, or cases requiring ethics-committee review). Most rework delays are documentation errors — not regulator obstruction. The practical implication is that getting the paperwork right on the first pass is the single highest-leverage thing a patient or physician can do to compress the timeline.

What Reserve Meds does

For Saudi Arabia, Reserve Meds coordinates US-side sourcing and supply documentation, aligns the pro-forma and DSCSA trail with the destination-country filing requirements, and ships under cold-chain where indicated. We do not file on the physician’s behalf — that is a matter for the licensed prescriber and their local counsel — but we provide the source-country documentation the filing needs, and we remain reachable by the physician through the cycle.

Further reading

See our country guidance pages for specific regulator contacts and current-cycle timelines, and our pathway explainers for the comparable mechanisms in other jurisdictions.

Start a request

Start a request